Introduction. Initiation and adjustment of antidepressant therapy require regular assessment of treatment adherence, medication tolerability, and changes in depressive symptoms. Digital communication channels, mobile applications, telemedicine-based models, and clinical decision support systems may facilitate such monitoring; however, their effectiveness largely depends on personalized feedback and specialist involvement. Aim: To summarize the evidence on the effectiveness, safety, and organizational models of digital pharmaceutical support for adults with depressive disorders. A systematic review was conducted in accordance with the PRISMA 2020 guidelines. The qualitative synthesis included 8 randomized controlled trials, while an additional 6 systematic reviews and meta-analyses were analyzed to contextualize the findings. The interventions included remote multidisciplinary care, secure messaging, mobile applications, systems for personalized antidepressant selection, and physician-prescribed digital therapeutics. The most consistent findings concerned improved adherence and continuity of treatment. Specialist-supported secure messaging increased the proportion of patients continuing treatment for more than 3 months from 61% to 81%. The PETRUSHKA system reduced treatment discontinuation from 27% to 17%, including discontinuation due to adverse reactions from 16% to 9%. Automated messaging without specialist involvement did not produce a significant effect. The effects of pharmacogenomics-guided systems and digital therapeutics on clinical response and remission were modest and heterogeneous. No Russian studies meeting the eligibility criteria were identified. Conclusion. A hybrid model appears to be the most appropriate approach: the digital service monitors medication use, symptoms, and adverse reactions; a healthcare professional provides personalized feedback and facilitates patient referral; and the treating physician makes decisions regarding treatment adjustment. Russian randomized controlled trials are required to evaluate the effectiveness of this model.
antidepressants; pharmaceutical support; digital technologies; medication adherence; telemedicine; clinical decision support systems; pharmacogenomics; depressive disorders
1. Brown JVE, Walton N, Meader N, Todd A, Webster LAD, Steele R, et al. Pharmacy-based management for depression in adults. Cochrane Database Syst Rev. 2019;12(12):CD013299. doi:https://doi.org/10.1002/14651858.CD013299.pub2.
2. Readdean KC, Heuer AJ, Parrott JS. Effect of pharmacist intervention on improving antidepressant medication adherence and depression symptomolo-gy: a systematic review and meta-analysis. Res Social Adm Pharm. 2018;14(4):321-31. doi:https://doi.org/10.1016/j.sapharm.2017.05.008.
3. González de León B, del Pino-Sedeño T, Serrano-Pérez P, Rodríguez Álvarez C, Bejarano-Quisoboni D, Trujillo-Martín MM. Effectiveness of interventions to improve medication adherence in adults with depressive dis-orders: a meta-analysis. BMC Psychia-try. 2022;22(1):487. doi:https://doi.org/10.1186/s12888-022-04120-w.
4. Leiz M, Pfeuffer N, Rehner L, Stentzel U, van den Berg N. Telemedi-cine as a tool to improve medicine ad-herence in patients with affective disor-ders: a systematic literature review. Patient Prefer Adherence. 2022;16:3441-63. doi:https://doi.org/10.2147/PPA.S388106.
5. Marasine NR, Sankhi S, Paudel S, Chalise A, Lamichhane R. Impact of pharmaceutical care interventions on antidepressants adherence and clinical outcomes in depressed patients: a sys-tematic review. Explor Res Clin Soc Pharm. 2025;20:100644. doi:https://doi.org/10.1016/j.rcsop.2025.100644.
6. Tesfamicael KG, Zhao L, Fer-nández-Rodríguez R, Adelson DL, Musker M, Polasek TM, et al. Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis. Front Psy-chiatry. 2024;15:1276410. doi:https://doi.org/10.3389/fpsyt.2024.1276410.
7. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 state-ment: an updated guideline for report-ing systematic reviews. BMJ. 2021;372:n71. doi:https://doi.org/10.1136/bmj.n71.
8. Cipriani A, Fernandes KBP, Mul-sant BH, Efthimiou O, Williams N, Mort S, et al; PETRUSHKA Team. A decision-support system to personalize antidepressant treatment in major de-pressive disorder: a randomized clinical trial. JAMA. 2026;335(14):1219-31. doi:https://doi.org/10.1001/jama.2026.1327.
9. Fortney JC, Pyne JM, Edlund MJ, Williams DK, Robinson DE, Mittal D, et al. A randomized trial of telemedi-cine-based collaborative care for de-pression. J Gen Intern Med. 2007;22(8):1086-93. doi:https://doi.org/10.1007/s11606-007-0201-9.
10. Simon GE, Ralston JD, Savarino J, Pabiniak C, Wentzel C, Operskalski BH. Randomized trial of depression fol-low-up care by online messaging. J Gen Intern Med. 2011;26(7):698-704. doi:https://doi.org/10.1007/s11606-011-1679-8.
11. Turvey C, Fuhrmeister L, Klein D, McCoy K, Moeckli J, Stewart Stef-fensmeier KR, et al. Secure messaging intervention in patients starting new an-tidepressant to promote adherence: pilot randomized controlled trial. JMIR Form Res. 2023;7:e51277. doi:https://doi.org/10.2196/51277.
12. Nianmongkon K, Samphao T, Nuchchom P, Tharavichitkun J, Jenraumjit R. Impact of a depression-specific pharmaceutical care counseling and smartphone app in medication ad-herence among patients with major de-pressive disorders: a pilot study. Pharm Pract (Granada). 2024;22:2969. doi:https://doi.org/10.18549/PharmPract.2024.1.2969.
13. Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, et al. Impact of pharmacogenomics on clinical outcomes in major depres-sive disorder in the GUIDED trial: a large, patient- and rater-blinded, ran-domized, controlled study. J Psychiatr Res. 2019;111:59-67. doi:https://doi.org/10.1016/j.jpsychires.2019.01.003.
14. Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, et al; PRIME Care Research Group. Effect of pharmacogenomic testing for drug-gene interactions on medication selec-tion and remission of symptoms in ma-jor depressive disorder: the PRIME Care randomized clinical trial. JAMA. 2022;328(2):151-61. doi:https://doi.org/10.1001/jama.2022.9805.
15. Rothman B, Slomkowski M, Speier A, Rush AJ, Trivedi MH, Lakhan SE, et al. A digital therapeutic (CT-152) as adjunct to antidepressant medication: a phase 3 randomized con-trolled trial (the Mirai study). J Affect Disord. 2025;388:119409. doi:https://doi.org/10.1016/j.jad.2025.119409.
16. Husain MI, Nigah Z, Ansari SUH, Khoso AB, Kiran T, Umer M, et al. Measurement-based care to enhance antidepressant treatment outcomes in major depressive disorder: a random-ized clinical trial. JAMA Netw Open. 2025;8(9):e2529427. doi:https://doi.org/10.1001/jamanetworkopen.2025.29427.
17. Hamlin M, Holmén J, Wentz E, Aiff H, Ali L, Steingrimsson S. Patient experience of digitalized follow-up of antidepressant treatment in psychiatric outpatient care: qualitative analysis. JMIR Ment Health. 2023;10:e48843. doi:https://doi.org/10.2196/48843
